| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 43.10 | -55 |
| Intrinsic value (DCF) | 31.36 | -68 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 43.40 | -55 |
Galenica AG is a leading Swiss healthcare service provider with a diversified business model spanning pharmacy retail, logistics, and IT solutions. Operating under brands like Amavita, Sun Store, and Coop Vitality, the company manages 520 pharmacies (368 owned, 152 partner pharmacies) across Switzerland, offering medication, consumer health products, and specialized healthcare services. Its Logistics & IT segment provides critical pre-wholesale pharmaceutical distribution, debt collection, and digital management solutions for pharmacies. Founded in 1927 and headquartered in Bern, Galenica plays a pivotal role in Switzerland’s healthcare ecosystem, combining retail reach with B2B logistics expertise. With a market cap of CHF 4.4 billion, the company serves as a key infrastructure player, bridging pharmaceutical manufacturers, healthcare providers, and end consumers. Its dual-segment approach ensures resilience, balancing steady pharmacy revenues with high-margin logistics and IT services.
Galenica AG presents a stable investment case anchored in Switzerland’s robust healthcare sector, characterized by low beta (0.29) and defensive cash flows. The company’s CHF 3.9 billion revenue and CHF 183 million net income reflect its entrenched market position, supported by a 3.7% dividend yield. Strengths include vertical integration (owning pharmacies + logistics) and recurring revenue from essential healthcare services. Risks include regulatory pressures on drug pricing and reliance on the Swiss market (89% of revenue). Capital expenditures are modest (CHF 37M), but debt (CHF 236M) warrants monitoring. The stock suits conservative investors seeking healthcare exposure with moderate growth (EPS: CHF 3.67) and downside protection.
Galenica’s competitive advantage stems from its integrated model, combining retail pharmacy dominance with proprietary logistics/IT infrastructure. Unlike pure-play pharmacy chains, its Logistics & IT segment provides high-margin B2B services (e.g., pharmaceutical pre-wholesale, pharmacy management software), creating cross-selling opportunities and sticky client relationships. The company’s 520-pharmacy network ensures unmatched local presence in Switzerland, while its IT solutions (e.g., master data systems) standardize workflows for partner pharmacies, enhancing switching costs. However, Galenica faces pricing pressure from online pharmacies and lacks significant international diversification. Its scale in logistics rivals smaller Swiss wholesalers but falls short of global giants like McKesson in technological sophistication. The dual-segment strategy mitigates retail margin erosion but requires sustained IT R&D investment to maintain edge against SaaS-focused competitors.